Beta-1 Selective Adrenoceptor Blocker (Cardioselective Beta-Blocker)
Atenolol
Brand names: Tenormin
Adult dose
Dose: Hypertension: 25–50 mg once daily; max 100 mg/day. Angina: 100 mg once daily (or 50 mg twice daily). AF rate control: 50–100 mg once daily. Post-MI: 50 mg within 12 hours then 50 mg 12 hourly
Route: Oral (also IV available for arrhythmias/MI: 5 mg over 5 min, repeat if needed)
Frequency: Once daily (most indications)
Clinical pearls
- Atenolol is no longer first-line for uncomplicated hypertension (NICE NG133 — beta-blockers now fourth-line unless compelling indication)
- Remains important post-MI, angina, AF rate control, and heart failure with reduced ejection fraction (HFrEF)
- Beta-1 selectivity at low doses — reduced risk of bronchospasm vs. non-selective beta-blockers (nadolol, propranolol), but still use with great caution in asthma/COPD
- Renal elimination — dose reduction required in severe renal impairment (eGFR <15)
- Never stop abruptly in angina or post-MI — wean gradually (rebound tachycardia/ischaemia)
- NICE NG185 (ACS): beta-blockers continued long-term post-STEMI
Contraindications
- Asthma / bronchospasm (beta-1 selective but risk in severe asthma)
- Second or third degree AV block (without pacemaker)
- Sick sinus syndrome
- Cardiogenic shock
- Severe peripheral arterial disease
- Uncontrolled heart failure
Side effects
- Bradycardia
- Fatigue, lethargy (very common)
- Cold extremities
- Sexual dysfunction (erectile dysfunction)
- Bronchospasm (in susceptible individuals)
- Hypoglycaemia masking (caution in insulin-treated diabetics)
- Worsening psoriasis
Interactions
- Calcium channel blockers (diltiazem, verapamil) — profound bradycardia/AV block; avoid combination
- Clonidine — rebound hypertension if clonidine stopped while on beta-blocker
- Digoxin — additive bradycardia
- NSAIDs — reduced antihypertensive effect
- Insulin/oral hypoglycaemics — hypoglycaemia symptoms masked
Monitoring
- Blood pressure and heart rate
- ECG (PR interval)
- Symptoms of peripheral arterial disease or Raynaud's
- Blood glucose in diabetics
- eGFR (dose adjust if needed)
Reference: BNF; NICE NG133 (Hypertension in adults, 2019 updated 2023); NICE NG185 (ACS, 2020); ESC/ESH Hypertension Guidelines (2023); https://bnf.nice.org.uk/drugs/atenolol/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Same class
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
Pathways
Same specialty
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines